NEW YORK (TheStreet) -- Gilead Sciences (GILD) shares are up 0.7% to $70.51 in trading on Monday following its appearance on Citigroup's (C) list of the top 50 "buy" rated stocks it covers.
Gilead Sciences estimated total investment return of 45.4% was the highest on the list.
Citigroup believes that the Sovaldi drug manufacturer will generate significant amounts of revenue that it could use to fund share buybacks, acquire companies to grow its pipeline and in 2-3 years potentially begin giving a dividend.
"Gilead is positioned to be the dominant player in the lucrative hepC market with a backdrop of a leading HIV franchise and a growing oncology franchise," said the report.
Twenty of the stocks on the Citigroup list are reviewed at Business Insider.
TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."